Table 3.
miRNA | Target Molecule | Related Skin Disease | Action Mechanism of miRNA | Reference |
---|---|---|---|---|
miR-339-5p ↓ | DLX5 | Increased involucrin expression through Wnt/β-catenin signaling pathway activation | [91] | |
miR-107 ↓ | Dicer | Increased filaggrin and loricrin expression | [92] | |
miR-203 (C/EBPα/miR-203 pathway) ↓ | ΔNp63α | HPV8 infection | Downregulation of involucrin | [66] |
miR-143 ↓ | IL-13Rα1 | Atopic dermatitis | Reduced filaggrin/ involucrin /loricrin expression through Th2-derived IL-13 activity stimulation | [12,93,94] |
Let-7a-5p ↓ | RRM2, CCR7 | Barrier abnormalities | [95] | |
miR-26a-5p ↓ | HAS3, DEPDC1B, DEPDC1, NAMPT, DENND1B, ADAM19 | [95] | ||
miR-10a-5p ↑ | HAS3 | [12] | ||
miR-29b ↑ | BCL2L2 | Barrier abnormalities with Increased IFN-γ-induced keratinocyte apoptosis | [12] | |
miR-6731-5p ↓ | S100A7 | IL-22-stimulated keratinocyte proliferation | [96] | |
miR-146a ↑ | EGFR | Terminal differentiation and proliferation inhibition in keratinocytes | [62] | |
miR-30a-3p ↓ | Familial acne inversa | Abnormal keratinocyte differentiation by accelerated EGFR degradation | [97] |
↑: upregulation, ↓: downregulation.